U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
CAMBRIDGE, Mass., May 04, 2017 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:
| What: | Vericel Corporation First-Quarter 2017 Earnings Call | ||||
| When: | Wednesday, May 10, 2017 at 8:00am (ET) | ||||
| Where: | http://investors.vcel.com/events.cfm | ||||
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. | ||||
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation first-quarter 2017 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until May 10, 2018. A replay of the call will also be available until 11:00 am (ET) on May 14, 2017 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 11385924.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
